Evidence map›Paper›PMID 17576838›Full record

ArticleAntimicrobial agents and chemotherapy2007

Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Joseph Meletiadis, Charalampos Antachopoulos, Theodouli Stergiopoulou, Spyros Pournaras, Emmanuel Roilides, Thomas J Walsh

Open access · greenAbstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Article
  3. Exploring the Epicarp Potential fromAntioxidants (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Precision-cut lung slices in air-liquid interface (PCLS-ALI): A novelbioRxiv : the preprint server for biology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Antimicrobial agents and chemotherapy · 2022
    Article
  13. Therapeutic Approaches for CombatingCurrent drug targets · 2022
    Review
  14. Article
  15. Article
  16. Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Joseph MeletiadisPediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Charalampos Antachopoulos
Theodouli Stergiopoulou
Spyros Pournaras
Emmanuel Roilides
Thomas J Walsh
National Cancer Institute · USHippocration General Hospital · GRUniversity Hospital of Larissa · GR

Funding

Treatment of Infections in Immunocompromised Children with Cancer, HematopoieticZ01SC006830 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI WALSH, THOMAS J. · 1996 to 2008
$5.8M
Treatment of Infections in Immunocompromised ChildrenZIASC006830 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WALSH, THOMAS J. · 2009 to 2009
$2.4M
Intramural NIH HHS
6 · The paper itself

Abstract

Antifungal agents may differ in their fungicidal activities against Aspergillus spp. In order to compare the fungicidal activities of voriconazole and amphotericin B against 40 isolates of Aspergillus fumigatus, A. flavus, and A. terreus, we developed a new microbroth colorimetric method for assessing fungicidal activities and determining minimal fungicidal concentrations (MFCs). This methodology follows the antifungal susceptibility testing reference method M-38A for MIC determination. After drug removal and addition of fresh medium, growth of viable conidia adhering to the bottoms of the microtitration wells was assessed by a colorimetric assay of metabolic activity after 24 h of incubation. The new method was faster (six times), reproducible (92 to 97%), and in agreement with culture-based MFCs (91 to 100%). Differential fungicidal activities of voriconazole and amphotericin B were found among the three Aspergillus species, with A. fumigatus and A. flavus having the lowest (1 and 2 mg/liter, respectively) and A. terreus the highest (>16 mg/liter) median amphotericin B MFCs; A. flavus had a lower median voriconazole MFC (4 mg/liter) than the other species (>8 mg/liter; P < 0.05). Amphotericin B was fungicidal (MFC/MIC </= 4) against all A. fumigatus and A. flavus isolates but no A. terreus isolates, whereas voriconazole was fungicidal against 82% of A. flavus isolates and fungistatic (MFC/MIC > 4) against 94% of A. fumigatus and 84% of A. terreus isolates. The new methodology revealed a concentration-dependent sigmoid pattern of fungicidal effects, indicating that fungicidal activity is not an all-or-nothing phenomenon and that some degree of fungicidal action can be found even for agents considered fungistatic based on the MFC/MIC ratio.

Indexed as

Amphotericin BAntifungal AgentsAspergillusColony Count, MicrobialColorimetryCulture MediaMicrobial Sensitivity TestsPyrimidinesQuality ControlRegression AnalysisReproducibility of ResultsSpecies SpecificitySpores, FungalTetrazolium SaltsTriazolesVitamin K 32,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxideAmphotericin BAntifungal AgentsCulture MediaPyrimidinesTetrazolium SaltsTriazolesVitamin K 3Voriconazole

Identifiers

PMID17576838
PMCPMC2043246
OpenAlexW2138700722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.